Sheba Medical Center

Paves way for additional large indications marketsTORONTO and HAIFA, Israel, Dec. 06, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based regenerative therapies, has announced significant findings from an expanded preclinical study of the potential of its portfolio drug, ExoPTEN, for repairing optic nerve damage. Conducted in collaboration with the Goldschleger Eye Institute at Sheba Medical Center, consistently ranked one of the top ten hospitals in the world1, the study builds on previously announced preliminary results2 on June 28, 2024 and strengthens the suggestion of a promising treatment pathway for glaucoma, the leading cause of irreversible blindness globally3. The Optic Nerve Disorders treatment market is expected to grow from 5.54 (USD Billion) in 2023 to 11.5 (USD Billion) by 2032, at a compound annual growth rate (CAGR) of ~8.46% during the forecast period4. Researchers utilized a rodent model of optic nerve crush (ONC) to simulate the damage associated with conditions like glaucoma. After inducing injury, ExoPTEN was administrated via direct injection into the eyes. The study expanded on earlier findings which indicated that eyes treated with ExoPTEN regained nearly normal retinal activity, as evidenced by electrical tests. Expanded analyses of the study data showed clear recovery of signal transmission in treated eyes compared to untreated controls, which showed no significant response. Additionally, imaging results by optical coherence tomography (OCT) scans indicates and validates that in all of treated eyes (naïve exosome treatment or ExoPTEN treatment) a successful ONC procedure has been performed (Figure 1). The study also showed that ExoPTEN treatment significantly enhanced the survival of retinal ganglion cells - key neurons responsible for transmitting visual information to the brain. Detailed analysis of retinal flat-mounts confirmed this effect, with treated eyes exhibiting substantially higher counts of these cells compared to untreated or control-treated eyes (Figures 2A and 2B). Dr. Ifat Sher, the lead investigator from the Goldschleger Eye Institute, commented, “the results from this expanded study are extremely encouraging. ExoPTEN demonstrates potential as a treatment that restores functionality and offers neuroprotection. The study shows clear signal recovery, healthier optic nerve structures and preserved retinal ganglion cells. These results suggest that ExoPTEN could fundamentally change how we approach conditions like glaucoma and optic nerve trauma. Encouraged by these results, we are advancing to a larger study with more animals to validate and expand upon these findings.” Dr. Lior Shaltiel, CEO of NurExone, added, “these findings are an important step forward in our mission to develop groundbreaking therapies for regenerative medicine in several indications. ExoPTEN’s ability to repair both the structure and function of the optic nerve highlights its transformative potential for addressing vision loss and improving tens of millions of patient lives.” About NurExone NurExone Biologic Inc. is a TSX Venture Exchange (“TSXV”) and OTCQB listed pharmaceutical company that is developing a platform for biologically guided exosome-based therapies to be delivered, minimally-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the United States Food and Drug Administration (FDA) and by the European Medicines Agency (EMA). The NurExone platform technology is expected to offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, X (formerly Twitter), Facebook or YouTube Dr. Lior ShaltielChief Executive Officer and DirectorPhone: +972-52-4803034Email: info@nurexone.com Oak Hill Financial Inc.2 Bloor Street, Suite 2900Toronto, Ontario M4W 3E2Investor Relations - CanadaPhone: +1-647-479-5803Email: info@oakhillfinancial.ca Dr. Eva ReuterInvestor Relations - GermanyPhone: +49-69-1532-5857Email: e.reuter@dr-reuter.eu Allele Capital PartnersInvestor Relations - USPhone: +1 978-857-5075Email: aeriksen@allelecapital.com FORWARD-LOOKING STATEMENTS This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the results of the Company’s preclinical trials and its suggestion of a promising treatment pathway for glaucoma; the growth of the Optic Nerve Disorders treatment market; the Company expanding to further studies; the Company developing groundbreaking therapies for regenerative medicine in several indications; ExoPTEN having the potential to address vision loss and improve patient lives; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the ability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the Company’s ability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company’s ability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine; the Optic Nerve Disorders treatment market continuing to grow as stated; the Company expanding to further studies; the Company developing groundbreaking therapies for regenerative medicine in several indications; ExoPTEN addressing vision loss and improve patient lives; and the NurExone platform technology will offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company’s early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; dependence on the Company’s strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company’s intellectual property and technology won’t have the intended impact on the Company and/or its business; the Company’s inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the Company’s inability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company’s inability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine; the Optic Nerve Disorders treatment market decreasing and/or plateauing; the Company’s inability to expand into further studies; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications; and the risks discussed under the heading “Risk Factors” on pages 44 to 51 of the Company’s Annual Information Form dated August 27, 2024, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law. Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. 1 https://www.afsmc.org/2024/02/sheba-medical-center-named-a-newsweek-worlds-best-hospital-for-the-6th-consecutive-year/2 https://www.globenewswire.com/news-release/2024/06/28/2906122/0/en/NurExone-s-ExoPTEN-Being-Studied-as-Glaucoma-Treatment-for-US-3-4-Billion-Market.html3 https://www.mdpi.com/1424-8247/17/10/12614 https://www.marketresearchfuture.com/reports/optic-nerve-disorders-treatment-market-30051 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5e682a60-3287-44b2-b7da-08ebed8fa807

TORONTO and HAIFA, Israel, Nov. 27, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce its financial and operational results for the three and nine months ended September 30, 2024, the highlights of which are included in this news release. The Company’s complete set of condensed interim consolidated financial statements for the three and nine months ended September 30, 2024, and accompanying management’s discussion and analysis for the period can be accessed by visiting the Company’s website at www.nurexone.com and its profile page on SEDAR+ at www.sedarplus.ca. Key Business Highlights In July 2024 and September 2024, the Company generated gross proceeds of C$143,172.05 through the issuance of 409,063 common shares upon the exercise of warrants at price of C$0.35 per common share which were issued in the Company’s January 2024 private placement.On August 1, 2024, the Company engaged Allele Capital Partners, LLC, an independently owned capital markets advisory firm based in the United States, for investor relations services.On September 26, 2024, the Company closed the first tranche of its non-brokered private placement through the issuance of 2,927,541 units at a price of C$0.55 per unit, resulting in aggregate gross proceeds of C$1,610,147.55. Each unit consisted of one common share and one common share purchase warrant, with each warrant entitling the holder thereof to purchase one additional common share at a price of C$0.70 per common share for a period of 36 months, subject to acceleration, as more particularly set out in the Company’s September 26, 2024 press release.On November 1, 2024, the Company closed the final tranche of its non-brokered private placement through the issuance of 231,818 units at a price of C$0.55 per unit, resulting in aggregate gross proceeds of C$127,499.90.On November 1, 2024, the Company engaged Independent Trading Group and Oak Hill Financial Inc. to provide market-making, business, and capital markets advisory services.On November 13, 2024, the Company announced that the European Medicines Agency granted Orphan Medicinal Product Designation for the Company’s ExoPTEN therapy, marking a significant step towards making this potential treatment available for acute spinal cord injury patients across Europe. Third Quarter Fiscal 2024 Financial Results Research and development expenses, net, were US$0.50 million in the third quarter of 2024, compared to US$0.40 million in the same quarter in 2023. The increase was primarily due to higher subcontractor and materials expenses of US$0.15 million, partially offset by a governmental grant receipt of US$0.05 million.General and administrative expenses were US$0.78 million in the third quarter of 2024, compared to US$0.76 million in the same period in 2023. The rise was mainly attributed to an increase in non-cash costs associated with granted stock options of US$0.17, partially offset by professional and legal services expenses of US$0.15 million.Finance income was US$0.04 million in the third quarter of 2024, compared to finance income of US$0.01 million in the same period in 2023, primarily due to income from bank interest and financing exchange rate adjustments.The net loss for the third quarter of 2024 was US$1.25 million, compared to a net loss of US$1.16 million in the same quarter of 2023. As of September 30, 2024, the Company held cash and cash equivalents totaling US$2.52 million, an increase from US$0.54 million as of December 31, 2023. The Company’s working capital also improved to US$2.39 million, up from US$0.07 million at the end of 2023. The increase in cash was primarily driven by the successful completion of private placements in January and September 2024, which generated gross proceeds of approximately US$2.68 million, as well as the exercise of warrants during 2024, yielding an additional US$3.30 million. These inflows were partially offset by a cash outflow of US$3.61 million related to operational activities. As of September 30, 2024, the Company had an accumulated deficit of US$17.55 million, compared to US$14.06 million as of December 31, 2023. Eran Ovadya, NurExone’s Chief Financial Officer, stated: “Our latest financial performance reflects our commitment to advancing ExoPTEN to clinical trials, while streamlining operations and optimizing our business strategy to drive sustainable growth and secure long-term success.” Growth Outlook for 2024-2025 According to Chief Executive Officer Dr. Lior Shaltiel, “NurExone is making significant strides on the path towards human trials, including the receipt of Orphan Drug Status for ExoPTEN in Europe, the successful transfer of key manufacturing processes to a Good Manufacturing Practice-compliant facility – an essential step toward clinical trials and commercial production. These efforts are being strengthened by our consultant, Dr. Yona Geffen, a highly respected expert who has successfully guided companies through the regulatory landscape to commercialization. In parallel, the Company is collaborating with the Goldschleger Eye Institute at Sheba Medical Center, ranked by Newsweek as one of the top ten hospitals in the world, to study ExoPTEN for its potential in a second commercial market, the multi-billion-dollar glaucoma market(1), with promising preliminary results.” About NurExone Biologic Inc. NurExone Biologic Inc. is a TSX Venture Exchange (“TSXV”) listed pharmaceutical company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior ShaltielChief Executive Officer and DirectorPhone: +972-52-4803034Email: info@nurexone.com Oak Hill Financial Inc.2 Bloor Street, Suite 2900Toronto, Ontario M4W 3E2Investor Relations - CanadaPhone: +1-647-479-5803Email: info@oakhillfinancial.ca Dr. Eva ReuterInvestment Relation - GermanyPhone: +49-69-1532-5857Email: e.reuter@dr-reuter.eu Allele Capital PartnersInvestment Relation - USPhone: +1 978-857-5075Email: aeriksen@allelecapital.com FORWARD-LOOKING STATEMENTS This press release contains certain “forward-looking statements”, that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to the receipt of the Orphan Medicinal Product Designation having the intended benefits and incentives on the Company and its business as set out herein; the potential glaucoma market; the Company having adequate financing through the end of the year and well into 2025; the Company entering the European market and bringing its products to patients across Europe; the Company’s latest financial performance positioning it for sustained growth and long-term success; the Company making significant strides on the path towards human trials with assistance from Dr. Yona Geffen; the Company collaborating with the Goldschleger Eye Institute at Sheba Medical Center to study ExoPTEN for its potential in a second commercial market, the multi-billion-dollar glaucoma market, with promising preliminary results; and the NurExone platform technology offering novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including the general business and economic conditions of the industries and countries in which we operate; the general market conditions; the ability to secure additional funding; partnerships having their intended impact on the Company and its business; patents safeguarding NurExone’s technology; the Company’s drug products having its intended benefits and effects; the Company making progress through new partnerships and technologies to move towards commercialization of their products; the Company’s intellectual property and technology being novel and inventive; the intellectual property having the intended impact on the Company and its business; exosomes becoming an ideal and natural choice for drug delivery; the Company making advancements in the manufacturing process of exosomes; exosomes holding immense promise for regenerative medicine; the Company’s preclinical and clinical testing will yield their intended results; the Company will proceed to clinical trials on the timelines setout herein; the Company will have sufficient funding for its operations; the Company will enter into new partnerships and/or licensing agreements; the receipt of the Orphan Medicinal Product Designation having the intended benefits and incentives on the Company and its business as set out herein; the Company will enter the European market and bring its products to patients across Europe; the Company being able to make significant strides on the path towards human trials with assistance from Dr. Yona Geffen; the Company being able to collaborate with the Goldschleger Eye Institute at Sheba Medical Center to study ExoPTEN for its potential in a second commercial market, the multi-billion-dollar glaucoma market, with promising preliminary results; the glaucoma market will grow; the Company will have adequate financing through the end of the year and well into 2025; the Company will position itself for sustained growth and long-term success; and the NurExone platform technology being able to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to the Company’s early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; protection of the Company’s intellectual property; dependence on the Company’s strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials and/or on the timelines set out herein; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; the Company being unable to have sustained growth and/or continued success; risks that the Company’s intellectual property and technology won’t have the intended impact on the Company and/or its business; the Company’s inability to realize upon partnerships; risks that the Company will not have adequate financing through the end of the year and/or well into 2025; risks that the Company will be unable to position itself for sustained growth and long-term success; the receipt of the Orphan Medicinal Product Designation not having the intended benefits and incentives on the Company and its business as set out herein; the Company not entering the European market and bringing its products to patients across Europe; risk that the Company will not make significant strides on the path towards human trials with assistance from Dr. Yona Geffen; risk that the Company will not collaborate with the Goldschleger Eye Institute at Sheba Medical Center to study ExoPTEN for its potential in a second commercial market, the multi-billion-dollar glaucoma market, with promising preliminary results already available; risk that the NurExone platform technology will be unable to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications; and the risks discussed under the heading “Risk Factors” on pages 44 to 51 of the Company’s Annual Information Form dated August 27, 2024, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law. Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. ___________________________(1) Global Glaucoma Treatment Market Analysis by Spherical Insights LLP

Pilot Results Presented at American Society of Consultant Pharmacists Annual Meeting Highlight FeelBetter's AI-Powered Platform's Success in Identifying Critical Medication Risks FeelBetter's Expansion into Long-Term Care and Skilled Nursing Facilities Includes Integration with PointClickCare, Optimizing Workflows and Increasing Efficiencies BOSTON, Nov. 12, 2024 /PRNewswire/ -- FeelBetter, a leader in AI-driven polypharmacy patient management, today announced a partnership with Americare, a leading long-term care and skilled nursing services provider, to help pinpoint residents at risk of adverse events due to complex medication regimens. This collaboration extends FeelBetter's reach into the long-term care and skilled nursing facility space to tackle the growing complexities of polypharmacy among seniors. As part of the expansion, FeelBetter has integrated with PointClickCare, the leading cloud-based healthcare platform for long-term and post-acute care providers, and will be available to its customers via the PointClickCare Marketplace. Results of an initial Americare pilot, presented at the American Society of Consultant Pharmacists (ASCP) Annual Meeting, underscore FeelBetter's impact. Conducted across eight Americare facilities and involving 370 residents, the pilot showed that FeelBetter's AI-powered platform can be used to accurately flag individuals for heightened medication-related risks, enabling more proactive, data-informed care decisions. "Polypharmacy is a complex challenge in senior care, and we're committed to finding innovative ways to address it," said James Dunham, RPh, Senior Vice President and Chief Operating Officer of Americare. "The pilot results are promising, showing how AI-driven insights can help our teams proactively flag at-risk patients and take early action to prevent potential adverse events. Through this partnership with FeelBetter, our goal is to bring a new level of responsiveness and precision to medication management, with the potential to significantly improve outcomes and quality of life for our residents." With more than 120 facilities across five states, Americare is known for its commitment to excellence in senior care, offering skilled nursing, assisted living, memory care, and rehabilitation services. Building on the pilot's success, Americare plans to expand its adoption of the FeelBetter platform across more of its facilities, integrating the technology into daily clinical workflows to enable real-time monitoring and decision support. "Expanding into the long-term care and skilled nursing space with Americare marks a significant milestone for us," said Liat Primor, FeelBetter's CEO. "We're committed to empowering clinical teams with the tools they need to proactively identify risks and respond quickly, particularly in environments where medication regimens can be complex. This partnership with Americare is an exciting opportunity to foster a proactive care culture that prioritizes the well-being of vulnerable populations." About FeelBetter FeelBetter is the pioneer of Pharmaco-Clinical Intelligence, changing the polypharmacy paradigm on both an individual and population health level with a comprehensive solution designed to tackle the challenges associated with suboptimal medication management. Powered by AI, FeelBetter's Pharmaco-Clinical Intelligence drives personalized medication management, helping healthcare professionals ensure that their patients' medication regimens are safe, effective, and appropriate. The technology pinpoints patients at high risk of deterioration and preventable hospitalization due to suboptimal medication management, and proactively suggests immediate and actionable interventions to reduce these risks. Provider organizations use FeelBetter to monitor their patients' progress and more proactively deliver the right follow-up care, as well as to efficiently allocate resources and minimize preventable, costly use of healthcare services. Led by an interdisciplinary team of clinicians, clinical pharmacists, and technologists, FeelBetter is headquartered in Boston and Tel Aviv. Investors include Firstime Ventures, Shoni Health Ventures, Triventures, ARC, the innovation hub of Sheba Medical Center, Random Forest VC, The Group Ventures, and GoodCompany Ventures. To learn more, visit feelbetter.healthcare. Contact: FeelBetter: Nicole Pariser [email protected] SOURCE FeelBetter WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED